<DOC>
	<DOCNO>NCT02208973</DOCNO>
	<brief_summary>To assess safety tolerability five dos PBF-680 ( 5 mg , 10 mg , 20 mg , 40 mg 60mg ) repeat ( 8 day ) single daily oral dose administration young male female healthy subject .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability Pharmacokinetic Profile PBF-680 After Multiple Oral Doses ''</brief_title>
	<detailed_description />
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Adenosine A1 Receptor Antagonists</mesh_term>
	<criteria>Subjects meet follow inclusion criterion screen visit : 1 . Healthy male female subject , 1845 year ( inclusive ) age time enrollment . 2 . Females must nonchildbearing potential ( i.e. , surgically sterile ) use contraceptive measure ( nonhormonal ) condom , diaphragm cervical/vault cap spermicide 28 day postadministration . Males agree abstain sexual intercourse female partner agree use condom spermicide , addition female partner use contraceptive measure 28 day postadministration . 3 . Clinically acceptable blood pressure pulse rate supine stand position . Blood pressure pulse measure minimum 3 minute rest . 4 . Body weight within normal range ( Quetelet 's index 19 26 ) express weight ( kg ) / height ( m2 ) . 5 . Able understand nature study comply requirement . 6 . Free acceptance participate study obtains sign informed consent form approve Ethics Committee Hospital ( CEIC ) . Subjects meet follow criterion screen visit exclude entry study : 1 . History serious adverse reaction hypersensitivity drug . 2 . Presence history allergy require acute chronic treatment ( except seasonal allergic rhinitis ) . 3 . Background clinical evidence chronic disease . 4 . Acute illness two week drug administration . 5 . Having undergone major surgery previous 6 month . 6 . Smokers ( refrain tobacco usage , include smokeless tobacco , nicotine patch , etc. , 6 month prior administration study medication . 7 . History alcohol dependence drug abuse last 5 year daily consumption alcohol &gt; 40 g men 24 gr/day woman high consumption stimulate beverage ( &gt; 5 coffee , tea coca cola drinks/ day ) sex . 8 . Abnormal physical finding clinical significance screen examination baseline would interfere objective study . 9 . Need prescription medication within 14 day prior administration drug non prescription medication herbal medicine within 7 day prior administration drug . 10 . Participation clinical trial previous 90 day investigational drug commercially available drug test . 11 . Having donate blood 4 week period inclusion study . 12 . Existence surgical medical condition might interfere absortion , distribution , metabolism excretion drug , i.e . impaired renal hepatic function , diabetes mellitus , cardiovascular abnormality , chronic symptom pronounce constipation diarrhea condition associate total partial obstruction urinary tract . 13 . 12 lead ECG obtain screen PR ≥ 220 msec , QRS ≥120 msec QTc ≥ 440 msec , bradychardia ( &lt; 50 bpm ) clinically significant minor ST wave change abnormal change screen ECG would interfere measurement QT interval . 14 . Symptoms significant somatic mental illness four week period precede drug administration . 15 . History hepatitis HBV / HCV / positive serology result indicate presence hepatitis B surface antigen / detectable HCV ribonucleic acid ( RNA ) . 16 . Positive result HIV serology . 17 . Females positive result pregnancy test breastfeeding . 18 . Clinically significant abnormal laboratory value ( determine Principal Investigator ) screen evaluation . 19 . Positive result drug screen period day start treatment period . A minimum list 6 drug screen inclusion : Amphetamines , Cocaine , Ethanol , Opiates , Cannabinoids Benzodiazepines ( positive result may repeat discretion Principal Investigator ) . 20 . Known hypersensitivity study drug composition galenical form . 21 . History psychiatric disease epileptic seizure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Adenosine A1 receptor antagonist</keyword>
	<keyword>adenosine receptor modulator</keyword>
	<keyword>Asthma</keyword>
	<keyword>COPD</keyword>
</DOC>